{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:22:15Z","timestamp":1793226135834,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.xphs.2023.07.012","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T02:03:18Z","timestamp":1689732198000},"page":"3131-3140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space"],"prefix":"10.1016","volume":"112","author":[{"given":"Everton","family":"Miranda dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto Gomes","family":"Ferraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6099-3687","authenticated-orcid":false,"given":"Michele Georges","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-9862","authenticated-orcid":false,"given":"Marcelo Dutra","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2023.07.012_bib0001","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/pharmaceutics14050892","article-title":"Development of extended release mini-tablets containing metoprolol supported by design of experiments and physiologically based biopharmaceutics modeling","volume":"14","author":"Issa","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2023.07.012_bib0002","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/03639045.2022.2102647","article-title":"Efficient drug development of oseltamivir capsules based on process control, bioequivalence and PBPK modeling","volume":"48","author":"Medeiros","year":"2022","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2023.07.012_bib0003","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1021\/acs.molpharmaceut.6b00497","article-title":"Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for lesinurad immediate release tablets","volume":"13","author":"Pepin","year":"2016","journal-title":"Mol Pharmaceut"},{"key":"10.1016\/j.xphs.2023.07.012_bib0004","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11095-022-03319-6","article-title":"Physiologically based pharmacokinetics modeling in biopharmaceutics: case studies for establishing the bioequivalence safe space for innovator and generic drugs","volume":"40","author":"Wu","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2023.07.012_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/pharmaceutics11050215","article-title":"In silico prediction of plasma concentrations of fluconazole capsules with different dissolution profiles and bioequivalence study using population simulation","volume":"11","author":"Duque","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2023.07.012_bib0006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5937\/arhfarm71-32479","article-title":"The emerging role of physiologically-based pharmacokinetic\/biopharmaceutics modeling in formulation development","volume":"71","author":"Cviji\u0107","year":"2021","journal-title":"Arh Farm"},{"key":"10.1016\/j.xphs.2023.07.012_bib0007","article-title":"Applications of PBPK\/PBBM modeling in generic product development: an industry perspective","volume":"69","author":"Yuvaneshwari","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.xphs.2023.07.012_bib0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejps.2014.10.018","article-title":"Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CY3A substrates using physiologically-based pharmacokinetic model","volume":"67","author":"Olivares-Morales","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.07.012_bib0009","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.xphs.2022.02.007","article-title":"A novel approach to justify dissolution differences in an extended-release drug product using physiologically based biopharmaceutics modeling and simulation","volume":"111","author":"Aishwarya","year":"2022","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.07.012_bib0010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/03639045.2021.1934870","article-title":"Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets","volume":"47","author":"Jaiswal","year":"2022","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2023.07.012_bib0011","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3390\/pharmaceutics15030882","article-title":"Use of in vitro dynamic colon model (DCM) to inform a physiologically based biopharmaceutic model (PBBM) to predict the in vivo performance of a modified-release formulation of theophylline","volume":"15","author":"Stamatopoulos","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2023.07.012_bib0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejpb.2022.12.001","article-title":"Model-informed drug development of gastroretentive release systems for sildenafil citrate","volume":"182","author":"Souza","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2023.07.012_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/281392","article-title":"Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets","volume":"281392","author":"Brioschi","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.xphs.2023.07.012_bib0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/0091270002042001007","article-title":"Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency","volume":"42","author":"Winchell","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2023.07.012_bib0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clinthera.2009.01.014","article-title":"A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double blind, two-period crossover study in healthy volunteers","volume":"31","author":"Darwish","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.xphs.2023.07.012_bib0016","series-title":"National Health Surveillance Agency","year":"2023"},{"key":"10.1016\/j.xphs.2023.07.012_bib0017","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tiv.2010.12.010","article-title":"A high content screening assay for identifying lysosomotropic compounds","volume":"25","author":"Nadanaciva","year":"2011","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.xphs.2023.07.012_bib0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.xphs.2018.09.036","article-title":"The irrelevance of in vitro dissolution in setting product specifications for drugs like dextromethorphan that are subject to lysosomal trapping","volume":"108","author":"Bolger","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.07.012_bib0019","series-title":"ASCPT 2016 ANNUAL MEETING Presentation number LB-026","article-title":"Rapid sublingual absorption of cyclobenzaprine (CBP) with basifying agents: prospect of bedtime treatment of fibromyalgia syndrome (FM)","author":"Daugherty","year":"2016"},{"key":"10.1016\/j.xphs.2023.07.012_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/bdd.2510030104","article-title":"Evidence for Route dependent biotransformation of cyclobenzaprine hydrochloride","volume":"3","author":"Till","year":"1982","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.xphs.2023.07.012_bib0021","unstructured":"FDA, Flexeril leaflet Reference ID: 3290967 (2013) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/017821s051lbl.pdf (accessed 03.16.2023)."},{"key":"10.1016\/j.xphs.2023.07.012_bib0022","unstructured":"M.G. Venkatesh, M.J. Clevenger, T. Grinstead, Preparation of controlled release skeletal muscle relaxant dosage forms, US Patent 8137734 B2 (2012). United States."},{"key":"10.1016\/j.xphs.2023.07.012_bib0023","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","article-title":"DDSolver: an add-in program for modeling and comparison of drug dissolution profiles","volume":"12","author":"Zhang","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2023.07.012_bib0024","first-page":"1","article-title":"Evaluation of the DDSolver software applications","volume":"204925","author":"Zuo","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.xphs.2023.07.012_bib0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1081\/DDC-120003007","article-title":"Investigation of the effect of tablet surface area\/volume on drug release from hydroxypropylmethylcellulose controlled-release matrix tablets","volume":"28","author":"Reynolds","year":"2002","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2023.07.012_bib0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/dmd.118.084541","article-title":"Quantitation of lysosomal trapping of basic lipophilic compounds using in vitro assays and in silico predictions based on the determination of the full pH profile of the endo-\/lysosomal system in rat hepatocytes","volume":"47","author":"Schmitt","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.xphs.2023.07.012_bib0027","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1208\/s12248-013-9555-6","article-title":"Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range \u2013 sotalol as a model drug","volume":"16","author":"Khalil","year":"2014","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2023.07.012_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2014.45","article-title":"Physiologically based pharmacokinetic modeling and simulations in pediatric drug development","volume":"3","author":"Maharaj","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2023.07.012_bib0029","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/psp4.12180","article-title":"Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: a desipramine case study","volume":"6","author":"Samant","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2023.07.012_bib0030","series-title":"GastroPlus\u00ae version 9.8.2 User Manual","year":"2021"},{"key":"10.1016\/j.xphs.2023.07.012_bib0031","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1023\/A:1018917729477","article-title":"Dissolution modeling: factors affecting the dissolution rates of polydisperse powders","volume":"10","author":"Lu","year":"1993","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2023.07.012_bib0032","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.xphs.2018.11.005","article-title":"Bioequivalence comparison of pediatric dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling","volume":"108","author":"Vaidhyanathan","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2023.07.012_bib0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11095-022-03319-6","article-title":"Physiologically based pharmacokinetics modeling in biopharmaceutics: case studies for establishing the bioequivalence safe space for innovator and generic drugs","volume":"40","author":"Wu","year":"2023","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2023.07.012_bib0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1208\/s12248-023-00787-5","article-title":"Establishing the safe space via physiologically based biopharmaceutics modeling. Case study: fevipiprant\/QAW039","volume":"25","author":"Kourentas","year":"2023","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2023.07.012_bib0035","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/psp4.12634","article-title":"Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: the case of bisoprolol","volume":"10","author":"Macwan","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2023.07.012_bib0036","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/pharmaceutics15051544","article-title":"Development of biopredictive dissolution method for extended-release desvenlafaxine tablets","volume":"15","author":"Carapeto","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923002885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923002885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:44:26Z","timestamp":1758361466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923002885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0022354923002885"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.07.012","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}